Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.48 |
| ▸ | PGR | P06401 | 12/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923996 | 1.00 | AR (0.48) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL13372614 | 0.88 | AR (0.46) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL13372564 | 0.88 | AR (0.46) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL925989 | 0.86 | AR (0.50) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL924304 | 0.86 | AR (0.50) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL984935 | 0.82 | PGR (0.57) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL923840 | 0.80 | PGR (0.58) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL926205 | 0.80 | PGR (0.58) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL3773112 | 0.80 | AR (0.48) | ARPGRNR3C2LMNACYP3A4 | |
| SCHEMBL16564526 | 0.79 | AR (0.46) | ARPGRNR3C2LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238150-B1 | 15,16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYLIC ACID y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | claimed |
| US-20110015162-A1 | 15,16-Methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid Y-lactone derivative, use thereof and medicinal products containing the derivative | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | claimed |
| US-20110015162-A1 | 15,16-Methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid Y-lactone derivative, use thereof and medicinal products containing the derivative | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015162-A1 | 15,16-Methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid Y-lactone derivative, use thereof and medicinal products containing the derivative | CYP17A1, CYP19A1, HSD17B7 | AR 48/4885PGR 29/4885NR3C2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.